Bristol Myers Squibb is the Most Undervalued Healthcare Stock in the S&P 500
Shares of Bristol Myers Squibb (BMY) are trading at a low valuation, with forward earnings multiples and free cash flow metrics suggesting it's one of the most undervalued healthcare stocks. Despite concerns over patent expirations for key drugs like Revlimid, recent results show growth from newer products is offsetting revenue declines.
Topics: Patent Expirations Pharmaceuticals Revenue Growth Stock Valuation